Literature DB >> 14631866

The action of ovarian hormones in cardiovascular disease.

Rodolfo A Medina1, Evelyn Aranda, Cesar Verdugo, Sumie Kato, Gareth I Owen.   

Abstract

The incidence of cardiovascular disease (CAD) differs between men and women, in part because of differences in risk factors and hormones. This sexual dimorphism means a lower incidence in atherosclerotic diseases in premenopausal women, which subsequently rises in postmenopausal women to eventually equal that of men. These observations point towards estrogen and progesterone playing a lifetime protective role against CAD in women. As exogenous estrogen and estrogen plus progesterone preparations produce significant reductions in low-density lipoprotein (LDL) cholesterol levels and significant increases in high-density lipoprotein (HDL) cholesterol, this should in theory lower the risk of CAD. However, results from oral contraceptive (OC) use and combined estrogen and progesterone hormone replacement therapy (HRT) have suggested that hormone replacement regimes do not provide cardiovascular protection. In fact, depending on the preparation and the presence or absence of genetic risk factors, an increased risk of cardiovascular diseases such as venous thrombosis, myocardial infarction (MI) and stroke have been observed. Interestingly, in the majority of studies the increase in risk was highest in the first year, after which an increase in risk was not observed, and in some studies a lower risk of CAD was evident after four or five years of exogenous hormone administration. While the debate continues about the merits of HRT, and several good reviews exist on the statistics of CAD in relation to exogenous hormones, we have decided to review the literature to piece together the physiological actions of estrogen and progesterone preparations on the individual mechanistic components leading to CAD; namely, the altered endothelium and the haemostatic balance between coagulation and fibrinolysis. We present possible mechanisms for how HRT and OCs protect against MI in the absence of cardiovascular risk factors but increase the incidence of MI in their presence. We also speculate on the roles played by hormones on the short- and long-term risks of cardiovascular disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14631866     DOI: 10.4067/s0716-97602003000300005

Source DB:  PubMed          Journal:  Biol Res        ISSN: 0716-9760            Impact factor:   5.612


  10 in total

1.  Progesterone regulation of tissue factor depends on MEK1/2 activation and requires the proline-rich site on progesterone receptor.

Authors:  Maria Loreto Bravo; Mauricio P Pinto; Ibeth Gonzalez; Barbara Oliva; Sumie Kato; Mauricio A Cuello; Carol A Lange; Gareth I Owen
Journal:  Endocrine       Date:  2014-05-23       Impact factor: 3.633

2.  Gender differences in neuropsychological performance in individuals with atherosclerosis: impact of vascular function.

Authors:  Caitlin S Moore; Ivy N Miller; Renee L Andersen; Stephan Arndt; William G Haynes; David J Moser
Journal:  J Clin Exp Neuropsychol       Date:  2010-05-28       Impact factor: 2.475

3.  In vivo and in vitro estrogenic and progestagenic actions of Tibolone.

Authors:  Anil Sadarangani; Ana María Salgado; Sumie Kato; Mauricio Pinto; Andrés Carvajal; Carolina Monso; Gareth I Owen; Pilar Vigil
Journal:  Biol Res       Date:  2005       Impact factor: 5.612

Review 4.  Progesterone in gender-affirming therapy of trans women.

Authors:  Charalampos Milionis; Ioannis Ilias; Eftychia Koukkou
Journal:  World J Biol Chem       Date:  2022-05-27

5.  Down-regulation of progesterone receptor membrane component 1 (PGRMC1) in peripheral nucleated blood cells associated with premature ovarian failure (POF) and polycystic ovary syndrome (PCOS).

Authors:  Jens Schuster; Teresia Karlsson; Per-Olof Karlström; Inger Sundström Poromaa; Niklas Dahl
Journal:  Reprod Biol Endocrinol       Date:  2010-06-10       Impact factor: 5.211

6.  Blood pressure reference values for European non-overweight school children: the IDEFICS study.

Authors:  G Barba; C Buck; K Bammann; C Hadjigeorgiou; A Hebestreit; S Mårild; D Molnár; P Russo; T Veidebaum; K Vyncke; W Ahrens; L A Moreno
Journal:  Int J Obes (Lond)       Date:  2014-09       Impact factor: 5.095

7.  Nuclear factor-kappaB regulates estrogen receptor-alpha transcription in the human heart.

Authors:  Shokoufeh Mahmoodzadeh; Stephan Fritschka; Elke Dworatzek; Thi H Pham; Eva Becher; Arne Kuehne; Mercy M Davidson; Vera Regitz-Zagrosek
Journal:  J Biol Chem       Date:  2009-07-06       Impact factor: 5.157

8.  Gender-Specific Associations between Circulating T-Cadherin and High Molecular Weight-Adiponectin in Patients with Stable Coronary Artery Disease.

Authors:  Andreas W Schoenenberger; Dennis Pfaff; Boris Dasen; Agne Frismantiene; Paul Erne; Therese J Resink; Maria Philippova
Journal:  PLoS One       Date:  2015-06-17       Impact factor: 3.240

9.  Hormone autocrination by vascularized hydrogel delivery of ovary spheroids to rescue ovarian dysfunctions.

Authors:  Hyo-Jin Yoon; Yong Jae Lee; Sewoom Baek; Young Shin Chung; Dae-Hyun Kim; Jae Hoon Lee; Yong Cheol Shin; Young Min Shin; Chungsoon Ryu; Hye-Seon Kim; So Hyun Ahn; Heeyon Kim; Young Bin Won; Inha Lee; Myung Jae Jeon; Si Hyun Cho; Byung Seok Lee; Hak-Joon Sung; Young Sik Choi
Journal:  Sci Adv       Date:  2021-04-28       Impact factor: 14.136

10.  Exposure to metal mixtures in relation to blood pressure among children 5-7 years old: An observational study in Bangladesh.

Authors:  Yu-Hsuan Shih; Caitlin G Howe; Molly Scannell Bryan; Mohammad Shahriar; Muhammad G Kibriya; Farzana Jasmine; Golam Sarwar; Joseph H Graziano; Victoria W Persky; Brian Jackson; Habibul Ahsan; Shohreh F Farzan; Maria Argos
Journal:  Environ Epidemiol       Date:  2021-02-11
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.